IHE iShares U.S. Pharmaceuticals ETF
- Health & Biotech Equities
IHE - Profile
- Issuer: iShares
- Structure: ETF
- Expense Ratio: 0.43%
- ETF Home Page: IHE
- Inception: May 01, 2006
- Tax Form: 1099
- IHE Tracks This Index: Dow Jones U.S. Select Pharmaceuticals Index
- 52 Week Lo: $123.25
- 52 Week Hi: $181.86
- AUM: $1,187.3 M
- Shares: 7.0 M
Alternative ETFs in the Health & Biotech Equities Category
|Type||Ticker||Expense Ratio||Assets||Avg. Daily Vol||YTD Return|
|Most Liquid (Volume)|
|Top YTD Performer|
The index measures the performance of the pharmaceuticals sector of the U.S. equity market.
IHE - Realtime Rating
Realtime Rating Summary
IHE is a passive ETF that seeks to replicate Dow Jones U.S. Select Pharmaceuticals Index. The index measures the performance of the pharmaceuticals sector of the U.S. equity market.
The adjacent table gives investors an individual Realtime Rating for IHE on several different metrics, including liquidity, expenses, performance, volatility, dividend, concentration of holdings in addition to an overall rating. The "A+ Metric Rated ETF" field, available to ETFdb Pro members, shows the ETF in the Health & Biotech Equities with the highest Metric Realtime Rating for each individual field. To view all of this data, sign up for a free 14-day trial for ETFdb Pro. To view information on how the ETFdb Realtime Ratings work, click here.
IHE In-Depth Analysis
The following tables and charts contain in-depth metrics for IHE and compare it to similar peer ETFs within its ETFdb Category.
IHE - HoldingsFilings Data as of: May 04, 2015
Top Ten Holdings
This section compares how balanced and deep IHE is relative to the peer group ETFdb Category.
IHE Asset Allocation
IHE Sector Breakdown
IHE Market Cap Breakdown
IHE Region Breakdown
IHE Market Tier Breakdown
IHE Country Breakdown
IHE - Expenses & Fees
This section compares the cost efficiency of IHE to peers in the same ETFdb Category.
Expenses Ratio Analysis
Commission Free Trading in IHE
IHE is not currently available for commission free trading on any platforms.
Category Commission Free Trading
There are 3 other ETFs in the Health & Biotech Equities ETFdb Category that are also eligible for commission free trading:
IHE - Performance
This section shows how IHE has performed relative to its peer group ETFdb Category.
IHE - Charts
The following charts can be customized to display historical performance in a number of different formats, including line charts, bar charts, and candlesticks. Time periods can be adjusted to increase or decrease the period shown, ranging from five minutes to several months.
The following chart also includes the option to compare the performance of IHE relative to other ETFs and benchmarks or to include indicators such as Bollinger Bands, relative strength, and moving averages.
IHE - Technicals
IHE Volatility Analysis
This section shows how the volatility of IHE compares to the peer group ETFdb Category.
- 20 Day MA: $175.77
- 60 Day MA: $171.58
- MACD 15 Period: -4.16
- MACD 100 Period: 7.13
- Williams % Range 10 Day: 64.59
- Williams % Range 20 Day: 64.59
- RSI 10 Day: 41
- RSI 20 Day: 47
- RSI 30 Day: 51
- Ultimate Oscillator: 40
IHE Bollinger Bands
- Lower Bollinger (10 Day): $167.03
- Upper Bollinger (10 Day): $182.50
- Lower Bollinger (20 Day): $169.21
- Upper Bollinger (20 Day): $182.39
- Lower Bollinger (30 Day): $168.26
- Upper Bollinger (30 Day): $181.50
IHE Support & Resistance
- Support Level 1: $170.92
- Support Level 2: $170.27
- Resistance Level 1: $172.61
- Resistance Level 2: $173.65
- Stochastic Oscillator %D (1 Day): 42.27
- Stochastic Oscillator %D (5 Day): 39.90
- Stochastic Oscillator %K (1 Day): 44.61
- Stochastic Oscillator %K (5 Day): 38.16
Latest IHE News
Which Pharmaceutical ETF Is Leading In Inflows? PJP vs. IHE vs. XPH
Checking In On Best And Worst Performers From 2011
Obama Victory Puts Healthcare ETFs In Focus
2014 Morningstar, Inc. All Rights Reserved. The information contained herein: ( 1 ) is proprietary to Morningstar and/or its content providers; ( 2 ) may not be copied or distributed; and ( 3 ) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.